List of Excipients in API cabozantinib
Excipients in NDA-approved (novel) drugs containing cabozantinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Exelixis Inc | CABOMETYX | cabozantinib | 42388-023 | ANHYDROUS LACTOSE | |
| Exelixis Inc | CABOMETYX | cabozantinib | 42388-023 | CELLULOSE, MICROCRYSTALLINE | |
| Exelixis Inc | CABOMETYX | cabozantinib | 42388-023 | CROSCARMELLOSE SODIUM | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for cabozantinib
Excipient focus: AMMONIA
cabozantinib drug variants containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
Excipient focus: ANHYDROUS LACTOSE
cabozantinib drug variants containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
Excipient focus: ASCORBYL PALMITATE
cabozantinib drug variants containing ASCORBYL PALMITATE
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing ASCORBYL PALMITATE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
cabozantinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
cabozantinib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
cabozantinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
cabozantinib drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
cabozantinib drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
cabozantinib drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSES
cabozantinib drug variants containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
cabozantinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
Excipient focus: POTASSIUM HYDROXIDE
cabozantinib drug variants containing POTASSIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing POTASSIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
cabozantinib drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
cabozantinib drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
cabozantinib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
Excipient focus: STEAROYL POLYOXYL-32 GLYCERIDES
cabozantinib drug variants containing STEAROYL POLYOXYL-32 GLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing STEAROYL POLYOXYL-32 GLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
cabozantinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TOCOPHEROL
cabozantinib drug variants containing TOCOPHEROL
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing TOCOPHEROL
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
cabozantinib drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Handa Pharma | cabozantinib laurylsulfate | 17201-011 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links